Catalyst

Slingshot members are tracking this event:

Sesen Bio (SESN) to Initiate Phase 2 Trial for Proxinium in Treatment of Late-Stage Squamous Cell Carcinoma of Head and Neck in H1 2017

Source Link:
http://ir.elevenbio.com/releasedetail.cfm?ReleaseID=990264

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
EBIO
100%
SESN Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Nov 20, 2017
Occurred Source:
http://ir.sesenbio.com/news-releases/news-release-details/eleven-biotherapeutics-reports-third-quarter-2017-financial
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Proxinium, Late-stage Squamous Cell Carcinoma, Head And Neck
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.